Sichuan Huichenxin Pharmaceutical

Sichuan Huichenxin Pharmaceutical is a wholly-owned subsidiary of Sichuan Huiyu Pharmaceutical (SSE: 688553), a prominent Chinese biopharmaceutical company specializing in oncology. Huichenxin functions as the commercial and distribution arm for the Huiyu group, managing the market entry and sales of both innovative therapies and high-quality generics. In August 2025, the company gained significant industry attention by entering into a master distribution agreement with TYK Medicines for the exclusive rights to commercialize TY-9591 (asandeutertinib) in mainland China. TY-9591 is a third-generation EGFR tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC), with a specific focus on patients with brain metastases.